IL6R and congenital rubella syndrome: IL6 is one of the most significantly elevated cytokines during CRS15 and becomes the focus of clinical interest in CRS management, as IL6 signaling blockade by Tocilizumab (targeting IL6R) has relieved the most life-threatening aspects of CRS in patients16.